Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, has entered a strategic partnership with Aquanova AG to jointly develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan.

“As we explore new ways to translate our scientific discoveries into tangible health solutions, we see an immense opportunity in the longevity and healthspan market,” said Christer Rosén, chairman and CEO of Jupiter Neurosciences. “Aquanova has been an exceptional technology partner, and their expertise in formulation and execution will be instrumental in this venture. We believe that our pharmaceutical-driven approach and the strong clinical foundation behind JOTROL provide a unique advantage in delivering high-quality, effective products to consumers.”

Jupiter and Aquanova have collaborated for over eight years in the development of Jupiter’s lead product, JOTROL, a proprietary resveratrol-based formulation currently advancing toward a Phase IIa trial in Parkinson’s Disease. Based on preclinical and clinical data supporting JOTROL’s potential in central nervous system (CNS) disorders such as Alzheimer’s and Parkinson’s, the companies are now leveraging their combined expertise to expand into the longevity and healthspan market.

The jointly developed products will focus on the concept of beauty from within, emphasizing scientifically backed formulations designed to support longevity and overall health. The first three products are expected to launch in Q3 2025 through a direct-to-consumer (DTC) model, providing an immediate commercial pathway while Jupiter continues its clinical development efforts.

“We are incredibly proud of our partnership with Jupiter and look forward to the work they are doing to bring life-changing solutions for rare and difficult-to-treat diseases to market in the medicinal sphere and for superior supplement products targeting longevity and healthspan,” said Frank Behnam, CEO of Aquanova. “Resveratrol is a powerful ingredient but it suffers from bioavailability and absorption challenges. Our NovaSOL technology ensures that resveratrol safely reaches effective levels in the body, without GI-side effects, creating reliable health solutions in many indications.”

As part of this initiative, Jupiter plans to launch these products under a new wholly owned subsidiary, allowing existing shareholders to participate in the commercial success of the venture. This subsidiary is expected to generate revenue which will support Jupiter’s ongoing pharmaceutical trials, the company said.

“We frequently hear from individuals interested in accessing JOTROL immediately, particularly those with personal connections to neurodegenerative diseases,” Rosén said. “Like many, I have seen the devastating impact of Alzheimer’s and Parkinson’s firsthand. This initiative not only represents a strategic business expansion but also a meaningful step in addressing a growing consumer demand for science-backed solutions in aging and healthspan.”